retatrutide weight loss trials Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful at 80 weeks in all doses in the Retatrutide Severe Obesity Trial Shows

Zepbound is in the same general class as Ozempic or Wegovy as an agonist of the GLP-1 receptor and has many similarities to those medications

Especially regarding the intestinal microbiota and increasing H

What is the difference between L-glutamine (L-glutamine) and glutathione supplementation for gut health and immune function?

The GLP-1 Pipeline Analysis 2026 The GLP-1 pipeline in 2026 is more competitive, more diversified, and more strategically important than at any point in the categorys history

et al., 2020 References Pickart L

Coordination of GPR40 and ketogenesis signaling by medium chain fatty acids regulates beta cell function